We report on a patient suffering from intractable itching secondary to intrahepatic cholestasis of pregnancy (ICP) unresponsive to conventional medical therapies. She was started on a regimen of therapeutic plasma exchange (TPE), which is often efficacious in relieving patient's itching from all causes of cholestasis, including ICP. We performed a retrospective review of a patient's medical record. Following initial TPE, the patient reported dramatic relief of her itching and consequent insomnia. However, this effect was short lived, as subsequent TPE provided minimal relief, and may have actually worsened her itching. Out of concern for poor fetal outcomes, delivery was induced at 34 weeks gestational age. The child had an uncomplicated neonatal intensive care unit stay following delivery, and the mother reported > 90% relief of her symptoms 2 weeks after delivery. TPE often provides longer term relief of itching because of ICP; however, it is not a panacea for these symptoms, and sometimes only delivery of the fetus can relieve maternal symptoms. In addition to the refractoriness to TPE, the case is also unusual for the early onset of ICP symptoms and the comorbidity of hepatitis C.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5730453 | PMC |
http://dx.doi.org/10.1055/s-0037-1609041 | DOI Listing |
Liver Int
February 2025
Division of Gastroenterology, Hepatology and Nutrition, The Hospital for Sick Children and the University of Toronto, Toronto, Ontario, Canada.
Background: Alagille syndrome (ALGS) is a multisystem cholestatic disorder. Maralixibat is approved for the treatment of cholestatic pruritus in ALGS with limited data in adults.
Methods: Participants were included if they received ≥ 2 doses of maralixibat at age ≥ 16 years in one of the three previously published maralixibat ALGS clinical trials.
Am J Transl Res
December 2024
Department of Reproductive Medicine Center, Changzhou Maternal and Child Health Care Hospital, Changzhou Medical Center, Nanjing Medical University Changzhou 213000, Jiangsu, China.
Background: Intrahepatic cholestasis of pregnancy (ICP) is the most common liver condition during pregnancy, associated with adverse outcomes for both mother and fetus. While inflammatory markers are important predictors in oncology and cardiovascular disease, their role in ICP remains unclear. This study investigates changes in platelet parameters and blood-derived inflammatory markers around the onset of ICP and evaluates their potential as independent risk factors.
View Article and Find Full Text PDFZ Geburtshilfe Neonatol
January 2025
Department of Obstetrics and Gynecology, Sichuan University West China Second University Hospital, Chengdu, China.
Intrahepatic cholestasis of pregnancy (ICP) is a pregnancy-specific liver disease characterized by pruritus and elevated total bile acid (TBA) levels. The most serious impact of ICP is sudden unexplained intrauterine fetal death, especially when an associated TBA ≥ 100 µmol/L is confirmed.We report a case of a 27-year-old female patient with early-onset severe refractory ICP.
View Article and Find Full Text PDFArq Bras Cir Dig
January 2025
Santa Casa de Misericórdia de Porto Alegre - Porto Alegre (RS), Brazil.
Background: Cholangiocarcinoma (CCA) is a rare neoplasm, with high mortality, originating in the bile ducts. Its incidence is higher in Eastern countries due to the endemic prevalence of liver parasites. Factors such as metabolic syndrome, smoking, and pro-inflammatory conditions are also linked to the disease.
View Article and Find Full Text PDFGinekol Pol
January 2025
Başakşehir Çam and Sakura City Hospital, Department of Perinatology, Istanbul, Türkiye.
Objectives: To investigate the roles of the systemic inflammatory response index (SIRI) and other biochemical markers obtained from maternal blood in determining the diagnosis and severity of pregnancy cholestasis.
Material And Methods: In this retrospective case-control study, a total of 815 pregnant women including 546 healthy pregnant women [serum total bile acid (TBA) level < 10 μmol/L, control group], 185 patients with mild cholestasis [serum TBA level < 40 μmol/L, mild intrahepatic cholestasis of pregnancy (ICP) group] and 84 patients with severe cholestasis (serum TBA level ≥ 40 μmol/L, severe ICP group) were evaluated. The groups were compared regarding demographic data, clinical characteristics, SIRI (neutrophilcount*monocytecount/lymphocyte count), and other laboratory data.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!